# reload+after+2024-01-23 18:45:20.556990
address1§3530 John Hopkins Court
city§San Diego
state§CA
zip§92121
country§United States
phone§858 633 0300
website§https://immunitybio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
fullTimeEmployees§670
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Patrick  Soon-Shiong F.A.C.S., FRCS (C), M.Sc.', 'age': 70, 'title': 'Executive Chairman of the Board, Global Chief Scientific & Medical Officer', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 629194, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Richard Gerald Adcock', 'age': 54, 'title': 'President, CEO & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 849450, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. David C. Sachs', 'age': 45, 'title': 'CFO, Principal Financial Officer & Principal Accounting Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 533327, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Barry J. Simon M.D.', 'age': 58, 'title': 'Chief Corporate Affairs Officer & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Leonard S. Sender M.D.', 'title': 'Chief Operating Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Enrique  Diloné Ph.D., RAC', 'age': 56, 'title': 'Chief Technology Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jason R. Liljestrom', 'age': 40, 'title': 'General Counsel & Corporate Secretary', 'yearBorn': 1983, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Sarah  Singleton', 'title': 'Chief Communications Officer & Head of Patient Advocacy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sandeep K. Reddy M.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Hans Georg Klingemann M.D., Ph.D.', 'age': 73, 'title': 'Chief Science Officer of Cellular', 'yearBorn': 1950, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§9
compensationRisk§7
shareHolderRightsRisk§6
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.181
priceToSalesTrailing12Months§5316.834
currency§USD
dateShortInterest§1702598400
forwardEps§-0.68
pegRatio§3.05
exchange§NMS
quoteType§EQUITY
shortName§ImmunityBio, Inc.
longName§ImmunityBio, Inc.
firstTradeDateEpochUtc§1438090200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§bd5d6a0c-fc2d-3cb7-b719-a9649d726d6f
gmtOffSetMilliseconds§-18000000
recommendationMean§3.0
recommendationKey§hold
quickRatio§2.127
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
